Literature DB >> 12357247

Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation.

Gareth R John1, Sai Latha Shankar, Bridget Shafit-Zagardo, Aldo Massimi, Sunhee C Lee, Cedric S Raine, Celia F Brosnan.   

Abstract

During mammalian central nervous system (CNS) development, contact-mediated activation of Notch1 receptors on oligodendrocyte precursors by the ligand Jagged1 induces Hes5, which inhibits maturation of these cells. Here we tested whether the Notch pathway is re-expressed in the adult CNS in multiple sclerosis (MS), an inflammatory demyelinating disease in which remyelination is typically limited. We found that transforming growth factor-beta 1 (TGF-beta 1), a cytokine upregulated in MS, specifically re-induced Jagged1 in primary cultures of human astrocytes. Within and around active MS plaques lacking remyelination, Jagged1 was expressed at high levels by hypertrophic astrocytes, whereas Notch1 and Hes5 localized to cells with an immature oligodendrocyte phenotype, and TGF-beta 1 was associated with perivascular extracellular matrix in the same areas. In contrast, there was negligible Jagged1 expression in remyelinated lesions. Experiments in vitro showed that Jagged1 signaling inhibited process outgrowth from primary human oligodendrocytes. These data are the first to implicate the Notch pathway in the limited remyelination in MS. Thus, Notch may represent a potential target for therapeutic intervention in this disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12357247     DOI: 10.1038/nm781

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  163 in total

1.  Investigation of astrocyte - oligodendrocyte interactions in human cultures.

Authors:  Gareth R John
Journal:  Methods Mol Biol       Date:  2012

Review 2.  The epigenetics of autoimmunity.

Authors:  Francesca Meda; Marco Folci; Andrea Baccarelli; Carlo Selmi
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

3.  Inflammation and remyelination in the central nervous system: a tale of two systems.

Authors:  Francesca Ruffini; Timothy E Kennedy; Jack P Antel
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

Review 4.  Notch and disease: a growing field.

Authors:  Angeliki Louvi; Spyros Artavanis-Tsakonas
Journal:  Semin Cell Dev Biol       Date:  2012-02-20       Impact factor: 7.727

Review 5.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

Review 6.  Pathophysiology of glia in perinatal white matter injury.

Authors:  Stephen A Back; Paul A Rosenberg
Journal:  Glia       Date:  2014-03-31       Impact factor: 7.452

7.  Arrested preoligodendrocyte maturation contributes to myelination failure in premature infants.

Authors:  Joshua R Buser; Jennifer Maire; Art Riddle; Xi Gong; Thuan Nguyen; Kerst Nelson; Ning Ling Luo; Jennifer Ren; Jaime Struve; Larry S Sherman; Steven P Miller; Vann Chau; Glenda Hendson; Praveen Ballabh; Marjorie R Grafe; Stephen A Back
Journal:  Ann Neurol       Date:  2012-01       Impact factor: 10.422

8.  Bone morphogenetic protein signaling and olig1/2 interact to regulate the differentiation and maturation of adult oligodendrocyte precursor cells.

Authors:  Xiaoxin Cheng; Yaping Wang; Qian He; Mengsheng Qiu; Scott R Whittemore; Qilin Cao
Journal:  Stem Cells       Date:  2007-09-13       Impact factor: 6.277

9.  Platelet-derived growth factor promotes repair of chronically demyelinated white matter.

Authors:  Adam C Vana; Nicole C Flint; Norah E Harwood; Tuan Q Le; Marcus Fruttiger; Regina C Armstrong
Journal:  J Neuropathol Exp Neurol       Date:  2007-11       Impact factor: 3.685

Review 10.  Myelin repair strategies: a cellular view.

Authors:  Vittorio Gallo; Regina C Armstrong
Journal:  Curr Opin Neurol       Date:  2008-06       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.